Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found.
By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. Likewise, the treatments produced near-complete remission in the animal models. The findings, which researchers said have significant potential for treating multiple sclerosis and other autoimmune disorders, are published today (Sept. 21) in the journal Molecular Therapy.
Multiple sclerosis affects about 2.3 million people worldwide and is the most common neurological disease in young adults. The incurable disorder starts when the immune system attacks the myelin sheath surrounding nerve fibers, making them misfire and leading to problems with muscle weakness, vision, speech and muscle coordination.
The researchers used a harmless virus, known as an adeno-associated virus, to deliver a gene responsible for a brain protein into the livers of the mouse models. The virus sparked production of so-called regulatory T cells, which suppress the immune system attack that defines multiple sclerosis. The gene was targeted to the liver because it has the ability to induce immune tolerance.
“Using a clinically tested gene therapy platform, we are able to induce very specific regulatory cells that target the self-reactive cells that are responsible for causing multiple sclerosis,” said Brad E. Hoffman, Ph.D., an assistant professor in the departments of pediatrics and neuroscience at the University of Florida College of Medicine.
The protein, myelin oligodendrocyte glycoprotein, was found to be effective in preventing and reversing muscular dystrophy on its own. A group of five mouse models that received the gene therapy did not develop experimental autoimmune encephalomyelitis, which is the mouse equivalent of multiple sclerosis in humans. In another experiment, all but one mouse model showed a significant reversal of the disease eight days after a single gene therapy treatment.
Hoffman said he was also encouraged by the treatment’s longevity. After seven months, the mouse models that were treated with gene therapy showed no signs of disease, compared with a group of untreated mouse models that had neurological problems after 14 days.
When the protein was combined with rapamycin — a drug used to coat heart stents and prevent organ transplant rejection — its effectiveness was further improved, the researchers found. The drug was chosen because it allows helpful regulatory T-cells to proliferate while blocking undesirable effector T-cells, Hoffman said.
Among the mouse models that were given rapamycin and the gene therapy, 71 percent and 80 percent went into near-complete remission after having hind-limb paralysis. That, Hoffman said, shows the combination can be especially effective at stopping rapidly progressing paralysis.
While researchers have established how gene therapy stimulates regulatory T cells in the liver, Hoffman said little else is known about the detailed mechanics of how that process works.
Before the therapy can be tested in humans during a clinical trial, further research involving other preclinical models will be needed, Hoffman said. Researchers also need to target the full suite of proteins that are implicated in multiple sclerosis, he added.
Still, Hoffman said he is extremely optimistic that the gene therapy can be effective in humans.
“If we can provide long-term remission for people and a long-term quality of life, that is a very promising outcome,” he said.
The Latest on: Multiple Sclerosis
- Walk creates awareness about multiple sclerosison February 2, 2020 at 4:13 pm
Hyderabad: People thronged the war memorial near Parade Ground, Secunderabad, early on Sunday morning for the Multiple Sclerosis (MS) Walk. The first Sunday of every February is marked as India MS Day ...
- GeNeuro raises €17.5M for multiple sclerosis clinical trialon January 31, 2020 at 4:35 am
GeNeuro has sold stock at a knock-down price to fund a multiple sclerosis trial. The €17.5 million ($19.3 million) private placement averts a cash crunch and sets GeNeuro up to test temelimab in MS ...
- Multiple Sclerosis Drugs Market 2020: Size, Share, Growth, Supply, Trends and Regional Forecast | Fortune Business Insights™on January 30, 2020 at 8:33 pm
The Multiple Sclerosis Drugs Market report offers insights into the latest trends. It highlights leading companies in the market and discusses the strategies that these companies have adopted in ...
- Biogen beats profit estimates on demand for multiple sclerosis drugon January 30, 2020 at 4:55 am
(Reuters) - Biogen Inc beat Wall Street expectations for quarterly profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera. Tecfidera revenue rose 4.5% to $1.16 ...
- Biogen's multiple sclerosis drug powers quarterly profit beaton January 30, 2020 at 4:10 am
Biogen Inc's top-selling multiple sclerosis drug helped the company's quarterly profit beat market expectations on Thursday, sending its shares up about 2% before the bell. Sales of Tecfidera rose 4.5 ...
- Biogen quarterly profit jumps on demand for multiple sclerosis drugon January 30, 2020 at 4:10 am
Drugmaker Biogen Inc reported a 52.1% jump in fourth-quarter profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera, and strength in biosimilars business. Net ...
- MSAA Recognizes 50 Years of Supporting the Multiple Sclerosis Communityon January 28, 2020 at 5:57 am
/PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA), founded in 1970, is proud to recognize its 50th Anniversary in 2020 as a ...
- 2020-26 Multiple Sclerosis Treatment Market Share by Top Companies Teva Pharmaceutical Industries, Bayer, Biogen Idecon January 26, 2020 at 10:21 pm
The Global Multiple Sclerosis Treatment Industry 2020 research report provides in-depth analysis by Top Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross ...
- With basketball, Mercer Island brothers bond, battle multiple sclerosis — and shoot for a cureon January 22, 2020 at 5:00 am
The difference now, however, is that Michael Schiller does his hooping in a wheelchair. He was diagnosed with multiple sclerosis 15 years ago, and has experienced a gradual decline in his physical ...
- Study shows how gene therapy may help protect against vision loss in multiple sclerosison January 21, 2020 at 7:13 pm
New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis ...
via Google News and Bing News